Related Experiment Video

Updated: May 28, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Mild cognitive impairment: historical development and summary of research

James Golomb1, Alan Kluger, Steven H Ferris

  • 1Department of Neurology, William & Sylvia Silberstein Institute for Aging and Dementia, New York University Medical Center, New York, NY.

Dialogues in Clinical Neuroscience
|October 29, 2011
PubMed

Insights

This review covers mild cognitive impairment (MCI), detailing its history, diagnosis, characteristics, and treatments. It examines various diagnostic methods and research approaches for understanding cognitive changes in aging populations.

Area of Science:

  • Gerontology
  • Neurology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
  • Understanding MCI is crucial for early intervention and managing cognitive decline in the elderly.

Purpose of the Study:

  • To provide a comprehensive overview of mild cognitive impairment (MCI).
  • To trace the historical development, diagnostic criteria, and clinical characteristics of MCI.
  • To review current and emerging treatment strategies for MCI.

Main Methods:

  • Literature review of historical development, diagnostic criteria, and clinical/neuropathological characteristics.
  • Analysis of various methodologies including clinical, neuropsychological, neuroimaging, biological, and molecular genetic approaches.
  • Examination of cross-sectional, longitudinal, and postmortem study results.

Main Results:

  • MCI is characterized by cognitive deficits beyond normal aging but not meeting dementia criteria.
  • Multiple approaches (clinical, neuropsychological, neuroimaging, genetic) are used to validate MCI.
  • Recent drug trials show varied results and highlight methodological challenges.

Conclusions:

  • MCI represents a spectrum of cognitive changes in aging.
  • Accurate diagnosis and characterization of MCI are essential for effective management.
  • Further research is needed to refine diagnostic criteria and develop effective treatments for MCI.
Keywords:
diagnostic criteriamild cognitive impairmentneuroimagingpathologypredictionprevalencetreatment

More Related Videos

Transcranial Direct Current Stimulation (tDCS) for Memory Enhancement10:37

Transcranial Direct Current Stimulation (tDCS) for Memory Enhancement

Published on: September 18, 2021

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...